Zum Hauptinhalt springen
ProhibitedBinding ruleKRNo English translationImport aus amtlicher Quelle geprüft

타크로리무스(tacrolimus), 그 염류 및유도체

Listed by the Korean MFDS as a substance that may not be used in cosmetics.

Regulatorische Entscheidung und vollständige Bedingungen

Status
Prohibited
Rechtsrolle
Binding rule
Regulatorische Zusammenfassung
Listed by the Korean MFDS as a substance that may not be used in cosmetics.
Bedingungen und Beschränkungen

타크로리무스

Stoffidentität

Name in der amtlichen Quelle
타크로리무스(tacrolimus), 그 염류 및유도체
CAS
104987-11-3
EC
Not supplied in this source row
Identitätszuordnung
standalone:official_korean_name

Marktübergreifende Übersicht zu dieser Identität

Exakte verknüpfte Einträge, die derzeit auf dieser Website vorhanden sind. Ein fehlender Markt bedeutet, dass kein exakter Treffer importiert wurde, nicht dass der Stoff verwendet werden darf.

1 Marktdatensatz
Chemische 2D-Struktur aus PubChem für CAS 104987-11-3
CAS 104987-11-3PubChem CID 445643

Verifizierte Chemie für CAS 104987-11-3

Tacrolimus

Tacrolimus is a calcineurin inhibitor and potent immunosuppressive agent used largely as a means of prophylaxis against cellular rejection after transplantation. Tacrolimus therapy can be associated with mild serum enzyme elevations, and it has been linked to rare instances of clinically apparent cholestatic liver injury. — LiverTox

IUPAC-Name
(1R,9S,12S,13R,14S,17R,18E,21S,23S,24R,25S,27R)-1,14-dihydroxy-12-[(E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23,25-dimethoxy-13,19,21,27-tetramethyl-17-prop-2-enyl-11,28-dioxa-4-azatricyclo[22.3.1.04,9]octacos-18-ene-2,3,10,16-tetrone
Summenformel
C44H69NO12
Molekulargewicht
804.0 g/mol
Exakte Masse
803.48197664 Da
Monoisotopische Masse
803.48197664 Da
XLogP3
2,7
Topologische polare Oberfläche
178,0 Ų
Molekulare Komplexität
1480,0
Formale Ladung
0
Wasserstoffbrücken-Donoren
3
Wasserstoffbrücken-Akzeptoren
12
Drehbare Bindungen
7
Schweratome
57
Kovalente Einheiten
1

An PubChem gemeldete Namen und Synonyme

FujimycinPrografTsukubaenolideAdvagrafModigrafProtopicTacrolimus anhydrousFK506
16 weitere gemeldete Namen
FK 506ProtopyAnhydrous TacrolimusTACROLIMUS MONOHYDRATEEnvarsusAvagrafFR-900506PrograftTacrolimus, anhydrousAstagraf XLEnvarsus XRTacrolimus (anhydrous)AdoportCapexionHecoriaPerixis
Kennungen in externen Datenbanken
Erweiterte Strukturstatistik
Definierte Atom-Stereozentren
14
Nicht definierte Atom-Stereozentren
0
Definierte Bindungs-Stereozentren
2
Nicht definierte Bindungs-Stereozentren
0
3D-Konformere
0
Maschinenlesbare Strukturkennungen
SMILES
C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](/C=C(/C1)\C)CC=C)O)C)/C(=C/[C@@H]4CC[C@H]([C@@H](C4)OC)O)/C)O)C)OC)OC
InChI
InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19+,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1
InChIKey
QJJXYPPXXYFBGM-LFZNUXCKSA-N

Belege aus weiteren wissenschaftlichen Datenbanken

EMBL-EBI ChEBI
Exakter KennungstrefferCHEBI:61049

tacrolimus (anhydrous)

A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.

Rezeptur
C44H69NO12
Durchschnittsmasse
804.031 g/mol
Monoisotopische Masse
803.48198 Da
Formale Ladung
0
  • macrolide lactam — is a (CHEBI:145565)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • bacterial metabolite — has role (CHEBI:76969)
  • immunosuppressive agent — has role (CHEBI:35705)
  • macrolide lactam — is a (CHEBI:145565)
Weitere kuratierte Namen
(3S,4R,5S,8R,9E,12S,14S,15R,16S,18R,19R,26aS)-5,19-dihydroxy-3-{(1E)-1-[(1R,3R,4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl}-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(prop-2-en-1-yl)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadec8-DEETHYL-8-[BUT-3-ENYL]-ASCOMYCIN(-)-FK 506FK 506FK506tacrolimusTacrolimustacrolimus anhydrous
Querverweise aus dieser Quelle
  • CAS: 104987-11-3 — KEGG COMPOUND
  • CAS: 104987-11-3 — ChemIDplus
  • CAS: 104987-11-3 — KEGG DRUG
  • REGISTRY_NUMBER: 3647477 — Reaxys
  • REGISTRY_NUMBER: 8821611 — Reaxys
  • MANUAL_X_REF: C01375 — KEGG COMPOUND
  • MANUAL_X_REF: D08556 — KEGG DRUG
  • MANUAL_X_REF: DB00864 — DrugBank
  • MANUAL_X_REF: EP184162 — Patent
  • MANUAL_X_REF: FK5 — PDBeChem
  • MANUAL_X_REF: LMPK04000003 — LIPID MAPS
  • MANUAL_X_REF: US5665727 — Patent

Zugeordnet durch: Exact CAS cross-reference in the ChEBI compound record. Quelle aktualisiert: 2019-12-03. Abgerufen: 2026-08-31. Quelleneintrag öffnen

NIH PubChem PUG-View
Exakter Kennungstreffer445643

Attributed physical-property, hazard, environmental and use annotations.

  • Exposure Routes: Absorption of tacrolimus from the gastrointestinal tract after oral administration is incomplete and variable. The absolute bioavailability in adult kidney transplant patients is 17Њ±10%; in adults liver transplant patients is 22Њ±6%; in healthy subjects is 18Њ±5%. The absolute bioavailability in pediatric liver transplant patients was 31Њ±24%. Tacrolimus maximum blood concentrations (Cmax) and area under the curve (AUC) appeared to increase in a dose-proportional fashion in 18 fasted healthy volunteers receiving a single oral dose of 3, 7, and 10 mg. When given without food, the rate and extent of absorption were the greatest. The time of the meal also affected bioavailability. When given immediately after a meal, mean Cmax was reduced 71%, and mean AUC was reduced 39%, relative to the fasted condition. When administered 1.5 hours following the meal, mean Cmax was reduced 63%, and mean AUC was reduced 39%, relative to the fasted condition. Quelle: Toxin and Toxin Target Database (T3DB)
  • Signal: Danger Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (97.6%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (92.7%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (91.5%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Quelle: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P203, P260, P264, P270, P280, P301+P316, P318, P319, P321, P330, P405, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 82 reports by companies from 13 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]; H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]; H372 (100%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure] Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. Quelle: European Chemicals Agency (ECHA)
  • Signal: Danger Quelle: Hazardous Substances Data Bank (HSDB)
  • GHS Hazard Statements: H301: Toxic if swallowed [Danger Acute toxicity, oral] Quelle: Hazardous Substances Data Bank (HSDB)
  • Precautionary Statement Codes: P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement) Quelle: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: IDENTIFICATION AND USE: Tacrolimus is white to off-white crystalline powder. It is a calcineurin-inhibitor immunosuppressant available in several preparations. Tacrolimus in both oral capsules and a solution for IV injection is used for prophylaxis of organ rejection in patients receiving liver, kidney or heart transplants. Tacrolimus topical ointment is used as a second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children. HUMAN EXPOSURE AND TOXICITY: While most acute overdosages of tacrolimus at up to 30 times the intended dose have been asymptomatic and all patients recovered with no sequelae, some acute overdosages were followed by adverse reactions including tremors, abnormal renal function, hypertension, and peripheral edema. At therapeutic doses, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin, as well as an increased risk of developing bacterial, viral, fungal, and protozoal infections, including opportunistic infections. These infections may lead to serious, including fatal, outcomes. While there a Quelle: Hazardous Substances Data Bank (HSDB)
  • Toxicity Summary: Signs and Symptoms of Overdose; Tacrolimus toxicity commonly presents as acute kidney injury. Close monitoring of serum creatinine, glomerular filtration rate, and urine output is necessary for patients on tacrolimus. Toxicity may also present as adverse effects, including tremors, electrolyte disturbances, and headaches. Monitor for neurotoxicity, nephrotoxicity, and hypertension. Investigations may indicate increased serum creatinine. An electrocardiogram should be obtained to rule out QT prolongation.; Management of Overdose; No specific antidote is currently available for tacrolimus toxicity, and the drug is not removed by hemodialysis. Management focuses on supportive care, including symptom monitoring and management. Consultation with the poison control center is recommended for current guidance and treatment recommendations. Quelle: StatPearls
  • Toxicity Summary: The mechanism of action of tacrolimus in atopic dermatitis is not known. While the following have been observed, the clinical significance of these observations in atopic dermatitis is not known. It has been demonstrated that tacrolimus inhibits T-lymphocyte activation by first binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines. Tacrolimus also inhibits the transcription for genes which encode IL-3, IL-4, IL-5, GM-CSF, and TNF-, all of which are involved in the early stages of T-cell activation. Additionally, tacrolimus has been shown to inhibit the release of pre-formed mediators from skin mast cells and basophils, and to downregulate the expression of FceRI on Langerhans cells. Quelle: Toxin and Toxin Target Database (T3DB)
  • Uses: THERAPEUTIC CATEGORY: Immunosupressant; dermatological treatment of atopic eczema Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Immunosuppressive Agents Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: MEDICATION Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >25; Use (kg) in USA (2002): 45; Consumption (g per capita; approx.) in Germany (2009): 0.000305; Consumption (g per capita) in the USA (2002): 0.00016; Calculated removal (%): 6 Quelle: NORMAN Suspect List Exchange
  • Uses: For use after allogenic organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It was first approved by the FDA in 1994 for use in liver transplantation, this has been extended to include kidney, heart, small bowel, pancreas, lung, trachea, skin, cornea, and limb transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis. Quelle: Toxin and Toxin Target Database (T3DB)

Zugeordnet durch: Existing checksum-valid CAS to unique PubChem CID match. Abgerufen: 2026-08-31. Quelleneintrag öffnen

Wissenschaftliche Klassifizierungen und Gefahrenannotationen liefern Kontext und ersetzen nicht die oben gezeigte marktspezifische regulatorische Entscheidung.

Weitere Quellenabdeckung und Trefferstatus
QuelleErgebnisGeprüft
EMBL-EBI ChEBIExakter Treffer2026-08-31
NIH PubChem PUG-ViewExakter Treffer2026-08-31

Ein erfasster Nicht-Treffer ist ein nützlicher Beleg dafür, dass die Quelle geprüft wurde; er ist keine Behauptung, dass der Stoff anderswo nicht existiert.

Am 2026-08-31 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.

Amtliche Quelle und Herkunft

Registrierte Quelle
South Korea MFDS cosmetic ingredient data
Quellenverweis
화장품 안전기준 등에 관한 규정, 별표 1, record 1-946
Eintrags-ID der Quelle
1-946
Quellenversion
2026-19
Quellsprache
Korean
Übersetzungsstatus
No English translation
Datum des Inkrafttretens
2026-03-18
Quelle aktualisiert
2026-03-18
Stand geprüft
2026-08-30 04:33 UTC
Validierungsmethode
MFDS JSON appendices 1–2 parse; 1077 prohibited, 243 restricted
SHA-256
056de35b843a5e31f709073f9e79d5e6e18f7c9164eb537bb099b185a37ef7d8

Hinweise zum registrierten Datensatz

Datensatzabdeckung
Ingredient identity and separate restriction/regulation data endpoints
Hinweis zur Behörde
Korean source is canonical; English materials alone are not complete enough for certification

Wie dieser Eintrag in den Marktdatensatz passt

1320
aktuelle Einträge für South Korea
1077
Einträge mit dem Status Prohibited
1320
Einträge aus dieser Quellenversion
1252
Markteinträge mit CAS-Identität

Statusverteilung

Bedingungstext ist bei 638 von 1320 aktuellen Einträgen vorhanden. Ein leeres Bedingungsfeld wird entsprechend der oben genannten Eintragsart interpretiert; es wird niemals in die Aussage einer uneingeschränkten Verwendung umgedeutet.

South Korea Marktkontext

Complete current appendix dataset

Abdeckungsversion: MFDS Notice 2026-19, effective 18 March 2026

All rows in official Appendix 1 (prohibited) and Appendix 2 (restricted) of the Safety Standards for Cosmetics.

Verifizierungs-Checkliste

  1. Match the Korean canonical substance name and identifiers.
  2. Review all Appendix 1 and 2 matches and conditions.
  3. Check functional-cosmetic and positive-list requirements where applicable.
  4. Confirm current MFDS notice, responsible seller and label obligations.

Amtliche Marktquellen

Verifizierungsablauf und Vollständigkeit des Eintrags

Bevor Sie dieses Ergebnis für eine Compliance-Entscheidung verwenden

  1. Bestätigen Sie, dass „타크로리무스(tacrolimus), 그 염류 및유도체“ und jede CAS-/EC-Kennung sich auf das Material in Ihrer Lieferantenspezifikation beziehen.
  2. Match the Korean canonical substance name and identifiers.
  3. Review all Appendix 1 and 2 matches and conditions.
  4. Check functional-cosmetic and positive-list requirements where applicable.
  5. Confirm current MFDS notice, responsible seller and label obligations.
  6. Dokumentieren Sie die Quellenversion und prüfen Sie die Behörde vor Herstellung, Notifizierung oder Inverkehrbringen erneut.

In diesem Eintrag verfügbare Felder

  • Amtlicher StoffnameVerfügbar
  • CASVerfügbar
  • ECNicht angegeben
  • Gesonderter BedingungstextVerfügbar
  • Datum des InkrafttretensVerfügbar
  • Snapshot-Hash und MethodeVerfügbar

Fragen, die diese Seite beantwortet

This official record identifies the substance as prohibited for cosmetic use in the stated market scope. Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

A prohibition entry may contain no separate condition text because the regulatory outcome is the prohibition itself. Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

Der Eintrag zitiert 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946, Quellenversion 2026-19. Die amtliche Quelle öffnen.

Nein. CAS hilft bei der Klärung der Identität, aber Rechtsordnungen können denselben Stoff unterschiedlich einstufen und unterschiedliche Produktbereiche, Grenzwerte, Warnhinweise und Übergangsfristen anwenden.

Dauerhafte Zitierweise

타크로리무스(tacrolimus), 그 염류 및유도체. 화장품 안전기준 등에 관한 규정, 별표 1, record 1-946. South Korea. Source version 2026-19. CosIng Checker regulatory record: https://cosingchecker.com/de/regulations/kr/records/1595/

Zitieren Sie die Aufsichtsbehörde als rechtliche Autorität. Diese Seite ist ein strukturierter Belegindex und eine Verifizierungshilfe, kein Ersatz für den amtlichen Text oder eine fachkundige rechtliche Bewertung.

Auslegung und Grenzen für South Korea

This official record identifies the substance as prohibited for cosmetic use in the stated market scope.

Do not rely on a formulation containing this identity until the cited source, effective date and exact substance match have been verified.

Wie die Rechtsrolle auszulegen ist

The cited row forms part of a binding rule or legally incorporated list for this market.

Belege auf dieser Seite

  • Erfasstes Ergebnis: Prohibited
  • Rechtsrolle: Binding rule
  • Quellenversion: 2026-19
  • Datum des Inkrafttretens: 2026-03-18

Was es nicht beweist

Korean source wording is canonical and other positive lists/notices may still apply to the formulation.

Weitere maßgebliche Stoffrecherche

Keine dieser Quellen hebt die oben genannte Marktentscheidung auf.

Cosmetic Ingredient Review safety assessments

Expert Panel conclusions, assessed ingredient groups, use conditions, dates and report documents

Independent expert review considered by FDA; not a government approval or binding market rule

Diese Identität bei der Quelle recherchieren

FDA Global Substance Registration System

UNII identifiers, preferred names, substance types, codes and public substance relationships

Identity registry only; UNII availability does not imply FDA review or approval

Diese Identität bei der Quelle recherchieren

ILO/WHO International Chemical Safety Cards

Hazards, symptoms, first aid, storage, incompatibilities and physical properties for covered chemicals

International occupational chemical-safety reference; not cosmetic-use approval

Diese Identität bei der Quelle recherchieren

Japan NITE-CHRIP

Chemical identity, Japanese and foreign legal lists, GHS hazards and exposure-related information

Chemical-management evidence; cosmetic status remains governed by the applicable MHLW standard and market rules

Diese Identität bei der Quelle recherchieren

NIOSH Pocket Guide to Chemical Hazards

REL, PEL, IDLH, properties, exposure routes, symptoms, target organs, first aid and measurement methods for covered workplace chemicals

US occupational-health guidance and limits; not a cosmetic ingredient decision

Diese Identität bei der Quelle recherchieren

OECD eChemPortal

Gateway to authority-owned physical-property, fate, ecotoxicity, toxicity, exposure and GHS records

Discovery gateway; each linked authority remains responsible for its data

Diese Identität bei der Quelle recherchieren

US EPA CompTox CTX APIs

Für den Import ist ein API-Schlüssel erforderlich

DTXSID identity, experimental and predicted properties, toxicity, bioactivity, exposure and environmental data

Scientific and computational evidence; predictions must remain labelled and do not determine cosmetic legality

Diese Identität bei der Quelle recherchieren